Shopping Cart (0) My Account
Models and Initiatives for Collaborations between Academia and Industry in Drug DiscoveryPre-Conference Symposium of the European Lab Automation 2012, Hamburg Date: May 29th 2012Time: 13:30 pm to 17:30 pmLocation: Radisson Blu Hotel, HamburgRegistration: Free of chargeAgendaThe symposium will give examples of the beneficial partnership models between Academia and the Pharmaceutical Industry by highlighting some of the positive outcomes of their joint research efforts. We will hear how this new collaborative trend drives innovation in Pharmaceutical Research and question its sustainability. Preliminary Agenda• Academic Screening and the NIH roadmap in the US by Hakim Djaballah, Director, Memorial Sloan-Kettering Cancer Center• Overview of the situation in Europe by Philip Gribbon, CSO, European Screening Port• 6 invited talks • Panel discussion Confirmed Speakers:- Catherine Kettleborough, Associate Director, MRCT Centre for Therapeutics Discovery UKTalk Title: MRC Technology: Discovering Novel Drugs with Academia- Bahne Stechmann, Scientific Manager, EU-OPENSCREENTalk Title: EU-OPENSCREEN - A European Infrastructure of Open Screening Platforms for Chemical Biology - Bert Klebl, Managing Director & Chief Scientific Officer, Lead-Discovery-CenterTalk Title: LDC – Max-Planck’s Hybrid Collaboration Model for Small Molecule Based Drug Discovery- Carole Fages, Head of the E2C Business Development Office, SanofiTalk Title: Sanofi Access Platform: A New Way of Partnering- Matthias Gottwald, Vice President Research Policy & Collaborations, Bayer Pharma AGTalk Title: EU Lead Factory – An Example of Bayer’s Activities in the Innovative Medicines Initiative IMI- Anton Ussi, Head of Operations, EATRIS European Infrastructure for Translational ResearchTalk Title: Bridging the Divide - Seeking Effective Translation Together with Academia